Breaking News From Pharma & Bio Ingredients
Pro-Pharmaceuticals Completes Colorectal Cancer Trial Enrollment
Posted on 2006-03-30 08:56:00
Pro-Pharmaceuticals, Inc., a developer of novel carbohydrate-based therapeutic compounds, today announced that patient enrollment has been successfully completed in Stage l of its Simon Two-Stage designed Phase II trial for third- and fourth-line treatment of colorectal cancer patients. In this Phase II study, patients with colon cancer, which has spread despite treatment with approved therapies, are receiving Davanat plus 5-Fluorouracil (5-FU) in monthly cycles for at least two cycles or until their disease progresses.
The study is designed to evaluate the safety and efficacy of Davanat plus 5-FU to shrink tumors or prevent further growth. These patients are refractory to 5-FU and have a minimum of 12 weeks to live. Dosing of patients began in May 2005. The company expects to report preliminary results in the second quarter of this year as patients continue to receive treatment.
Davanat is a proprietary polysaccharide polymer comprised of mannose and galactose carbohydrates in a Carbosome formation that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) on cancer cells.
Subscribe via RSS
